Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors
Journal of Hematopathology · 2024
DOI: 10.1007/s12308-024-00612-8 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Hematopathology, 2024. Verfasst von William Patrick Morrow und 12 weiteren Autor:innen. Beteiligte Einrichtung: Wake Forest Baptist Health, Winston-Salem, NC, USA. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Lymphoma, Large-Cell, Anaplastic, Central Nervous System Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Anaplastic large cell lymphoma with primary presentation in, and disease limited to, the central nervous system (primary CNS ALCL) is a rare and aggressive lymphoma found in a sensitive anatomic site. We report the clinical and pathologic characteristics of 17 primary CNS ALCL cases that are newly reported from six academic medical centers. We are investigating the characteristics of these cases, alongside their commonalities and differences from systemic ALCL arising at conventional anatomic sites. Clinical, pathologic, and outcome data were extracted by medical record review. The median patient age was 32 years with a male-to-female ratio of 2.4:1. Cases presented with either localized or multifocal central nervous system (CNS) disease without coinciding systemic disease. Histologically, the common pattern prevailed, and loss of pan-T-cell markers was frequent. There was a similar proportion of anaplastic lymphoma kinase (ALK) positivity in primary CNS ALCL (12/17, 71%) compared to that reported in systemic ALCL (70-80%). Our data indicate a 5-year overall survival (OS) rate of 65% and a 5-year progression-free survival (PFS) rate of 48%. Five patient deaths occurred in this study of which all were in the ALK-negative group, and all were patients over 40 years old. ALK-positive patients were significantly younger than ALK-negative patients, and survival analyses showed that both ALK-positive and younger age (≤ 40 years) were favorable prognostic factors. This is the largest series of primary CNS ALCL reported to date, which demonstrates a high proportion of ALK-positive cases and favorable outcomes for both younger and ALK-positive patients despite the involvement of a sensitive anatomic site.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wake Forest Baptist Health, Winston-Salem, NC, USA.
- University of California San Francisco, San Francisco, CA, USA.
- Duke University Medical Center, Durham, NC, USA.
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Mayo Clinic, Rochester, MN, USA.
- BC Cancer Centre for Lymphoid Cancer, Vancouver, Canada.
Zitieren
APA
Morrow, W. P., Milligan, N. S., Ohgami, R. S., Young, K. H., Wang, B., Vega, F., Marques-Piubelli, M. L., Feldman, A. L., Slack, G. W., Savage, K. J., Zhao, X., Rubenstein, J. L., & Hsi, E. D. (2024). Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors. Journal of Hematopathology. https://doi.org/10.1007/s12308-024-00612-8
Vancouver
Morrow WP, Milligan NS, Ohgami RS, Young KH, Wang B, Vega F, et al. Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors. Journal of Hematopathology. 2024. doi:10.1007/s12308-024-00612-8
BibTeX
@article{Morrow2024,
author = {Morrow, William Patrick and Milligan, Nicholas S and Ohgami, Robert S and Young, Ken H and Wang, Bangchen and Vega, Francisco and Marques-Piubelli, Mario L and Feldman, Andrew L and Slack, Graham W and Savage, Kerry J and Zhao, Xiaoxian and Rubenstein, James L and Hsi, Eric D},
title = {Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors},
journal = {Journal of Hematopathology},
year = {2024},
doi = {10.1007/s12308-024-00612-8}
}
EUVIMED